Cuba and China strengthen ties in biotechnology

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Cuba and China strengthen ties in biotechnology

Home/Pharma News | Posted 01/09/2023 0 Post your comment

The biotechnological cooperation between Cuba and China has been a longstanding relationship in the scientific and technological realms. For the benefit of both countries, Havana and Beijing have undertaken various collaborations in the field of biotechnology, driven by their bilateral relations and shared interest in the development of the healthcare and pharmaceutical industry.

Recently, the two countries have taken new steps to further deepen their cooperation in biotechnology by signing a technology transfer contract for the research, production and development of a medicine designed to treat different types of cancer.

Currently, the two countries operate three companies in Chinese territory that oversee five manufacturing plants, which incorporate Cuban technology. Over the last 20 years, they have undertaken more than 30 joint projects, including those related to monoclonal antibodies and interferons, marketed in China and other states.

In the Asian giant, various Cuban biotechnological products are present, such as Nimotuzumab, used for the treatment of pancreatic cancer. In fact, during the COVID-19 pandemic, on Chinese territory, the Interferon Alfa 2B recombinant treatment was used for individuals infected by the virus.

Part of these advances includes the establishment of the China-Cuba Joint Innovation Center in Biotechnology in the Yongzhou Economic and Technological Development Zone. This centre is the first of its kind in the realm of scientific and technical collaboration.

The scientific cooperation between Cuba and China in the field of health is an example of collaboration between two countries that share a common vision regarding the importance of research and development in improving the health and well-being of their populations [1].

Pharmaceutical companies in China manufacturing copy biologicals

LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Seminario web sobre el cambio no médico de biológicos/biosimilares: Canadá, Europa y EE.UU.

Browse the news in the Latin American Forum!

FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Seminario web sobre el cambio no médico de biológicos/biosimilares: Canadá, Europa y EE.UU.

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Cuba and China strengthen scientific cooperation for the development of medical treatments [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Sep 1]. Available from: www.gabionline.net/pharma-news/cuba-and-china-strengthen-scientific-cooperation-for-the-development-of-medical-treatments

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.